Immunogen (IMGN) Tops Q1 EPS by 2c, Revenues Miss; Offers 2Q Revenues Outlook
Get Alerts IMGN Hot Sheet
Revenue Growth %: -100.0%
Financial Fact:
License and milestone fees: 76K
Today's EPS Names:
NLY, CP, RUSHA, More
Join SI Premium – FREE
Immunogen (NASDAQ: IMGN) reported Q1 EPS of ($0.17), $0.02 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $15.55 million versus the consensus estimate of $17.73 million.
"During the first quarter, we advanced our portfolio of innovative ADCs and accelerated preparations for two potential product launches next year," said Mark Enyedy, ImmunoGen's President and Chief Executive Officer. "We saw a limited delay in patient enrollment in the pivotal SORAYA trial for our lead program, mirvetuximab soravtansine, which has shifted the anticipated timing of top-line data from the third into the fourth quarter of this year and the projected submission of the BLA into the first quarter of 2022. We have also experienced some COVID-related impact on accrual to our confirmatory MIRASOL trial and now expect the read-out on the primary endpoint to move from the second into the third quarter of 2022. Beyond SORAYA and MIRASOL, we are commencing several studies to move mirvetuximab into earlier lines of ovarian cancer therapy, including an investigator-sponsored trial of mirvetuximab in combination with carboplatin in the neoadjuvant setting that initiated this quarter. We are also supporting a randomized study comparing mirvetuximab combined with carboplatin to standard of care in patients with recurrent platinum-sensitive disease and have submitted a protocol to FDA for a single-arm study of mirvetuximab monotherapy in later-line platinum-sensitive patients, with both studies anticipated to begin enrollment in the second half of this year. Finally, we were pleased to receive notice that mature data from our mirvetuximab plus AvastinĀ® doublet cohort in recurrent ovarian cancer, regardless of platinum status, have been selected for an oral presentation at ASCO in June."
Enyedy added, "We continued enrollment for our second pivotal program, IMGN632, in patients with frontline and relapsed/refractory BPDCN, with top-line data expected in the first half of 2022. IMGN632 is also in ongoing development in AML, both as a monotherapy and in combinations. Moving to our earlier-stage portfolio, we presented preclinical data at AACR last month on IMGC936, our first-in-class ADAM9-targeting ADC, demonstrating anti-tumor activity in multiple solid tumor models, and we advanced dose escalation in the Phase 1 study for this program. IND-enabling activities for our next-generation anti-FRĪ± ADC, IMGN151, are on track to submit an application to the FDA by the end of 2021. With pre-commercial activities underway, we look forward to a meaningful year ahead with a number of important milestones across the business as we work towards bringing our first two therapies to market next year."
GUIDANCE:
Immunogen sees Q2 2021 revenue of $65-75 million, versus the consensus of $70.02 million.
ImmunoGen's financial guidance for 2021 remains unchanged:
- revenues between $65 million and $75 million;
- operating expenses between $200 million and $210 million; and
- cash and cash equivalents at December 31, 2021 to be between $140 million and $150 million.
ImmunoGen expects that its current cash will fund operations into the second half of 2022.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nanometrics (NANO) Issues Business Update, Reports FY23 Results
- First Bancshares (FBMS) Tops Q1 EPS by 6c
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
Create E-mail Alert Related Categories
Corporate News, Earnings, Guidance, Management CommentsRelated Entities
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!